Briefings for Michal

- PRIA/registration overview 2/23rd (complete)
- Dicamba 2/18th (complete)
- Sulfoxaflor 3/4th (complete)
- Pet incidents 3/31st (complete)
- FDA/EPA jurisdiction 4/12th (complete)
- SW2 revocation options 5/3rd (complete)
- Antibiotics $-5/17^{th}$

Urgent

PRIA Do not grant letters – need to be signed today or renegotiated

New Active Ingredients (include original PRIA date)

- Tetraniliprole completed!
- Broflanilide completed!
- Picarbutrazox completed!
- Fluxametamide completed!
- Fluindapyr PD signed. PRIA Date 5/14/21 (Original PRIA date 5/29/20) (FB) FD with OPP-IO for review
- Trifludimoxazin PD signed. PRIA date 5/26/21 (Original PRIA date 10/16/2020) (FHB) –
 FD with OPP-IO for signature
- Rekleml PD being developed. PRIA date 7/19/21 (Original PRIA date 4/19/21) (IVB3). Partial ESA causing delays
- Ipflufenoquin PD being developed. PRIA date 7/30/31 (Original PRIA date 4/19/21) (FB). Working on ESA causing delays
- L-Glufosinate Ammonium Risk Assessment phase. PRIA date 10/12/2021. ESA issue. Any feedback?

Other Chemical Actions

Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

Other Actions - AA-Level/OD/High Visibility Items

Ex. 5 Deliberative Process (DP)

• COVID-19 Activities – Sect 18s -

Ex. 5 Deliberative Process (DP)

OIG Audits

Ex. 5 Deliberative Process (DP)

• **PFAS** – RD working with Clark on submissions

Ex. 5 Deliberative Process (DP)

Inerts supply issue – phase 1 completed!; phase 2 – additional considerations

International

• Bi-monthly meeting with PMRA 5/11th – antibiotics, Seresto

Business/process/technology

- ISB FEP/21-day backlog:
 - backlog addressed by end of April; RD SWAT team addressing newer receipts
 - Working to complete RD SWAT actions

• eCSF/OPPEL – ITRMD report May 9th soft launch;

Speaking Engagements -

People/Personnel/Resources

Ex. 6 Personal Privacy (PP)

CA topics (Karen Morrison):

Ex. 5 Deliberative Process (DP)